Application of the Euro Clonality next‐generation sequencing‐based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial-Reference-Cited by-同舟云学术

Application of the Euro Clonality next‐generation sequencing‐based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial

Published:2021-05-18 Issue:2 Volume:194 Page:378-381
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Genuardi Elisa¹^ORCID,Romano Greta²³⁴,Beccuti Marco²,Alessandria Beatrice¹,Mannina Donato⁵,Califano Catello⁶,Rota Scalabrini Delia⁷,Cortelazzo Sergio⁸,Ladetto Marco⁹,Ferrero Simone¹¹⁰,Calogero Raffaele A.¹¹,Cordero Francesca²

Affiliation:

1. Department of Molecular Biotechnologies and Health Sciences ‐ Hematology Division University of Torino TorinoItaly

2. Department of Computer Sciences University of Torino TorinoItaly

3. IIGM ‐ Italian Institute for Genomic Medicine, c/o IRCCS Candiolo (Torino)Italy

4. Candiolo Cancer InstituteFPO ‐ IRCCS CandioloItaly

5. Azienda Ospedaliera Papardo‐ UOC di Ematologia MessinaItaly

6. U.O.C. Ematologia P.O. Pagani SalernoItaly

7. Ematologia Fondazione del Piemonte per l’Oncologia – IRCCS CandioloItaly

8. Oncology Unit Clinica Humanitas/Gavazzeni BergamoItaly

9. Division of Hematology Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo AlessandriaItaly

10. Hematology Division AOU “Città della Salute e della Scienza di Torino” TorinoItaly

11. Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy

Funder

Fondazione CRT

Cancer Research UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17519

Reference15 articles.

1. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

2. Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

3. Minimal Residual Disease Detection in Mantle Cell Lymphoma: Technical Aspects and Clinical Relevance

4. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data

5. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial;Journal of Clinical Oncology;2023-11-22

2. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma;Current Treatment Options in Oncology;2023-05-30

3. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma;Blood;2022-09-22

4. Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside;Experimental Hematology & Oncology;2022-09-03

5. Next-Generation Sequencing–Based Antigen-Receptor Gene Clonality Assays;The Journal of Molecular Diagnostics;2021-09